It is known that activating mutations in the HRAS homolog, KRAS, decrease gefitinib sensitivity in NSCLC [58, 59], and that activation of the PIK3CA pathway also reduces tyrosine kinase inhibitor sensitivity in EGFR-mutant lung cancers [60–63]. Here, HRAS is linked to non-small cell lung carcinoma.